Introduction
The availability of hypothalamic-releasing hormones together with reliable assays of pituitary hormones in plasma have provided the means of accurate assessment of hypothalamic-pituitary function. A case is described of clinical hypopituitarism following radiotherapy to the head and neck, in which the use of these pituitary function tests has demonstrated damage at the hypothalamic level.
Case Report
A 53-year-old postmenopausal woman presented in 1973 with cervical lymphadenopathy, the histology of which was interpreted as an unspecifiable form of malignant lymphoma. She Her BP increased to 120/90 mmHg, and plasma electrolytes returned to normal. While previously she had been so weak that she had had difficulty sitting up in bed, within 2 days of starting treatment, she had recovered normal muscle power. Two months after starting replacement therapy, her weight had increased by 5 kg. There was no clinical evidence of persisting hypopituitarism but the serum prolactin level remained markedly elevated at 2240 mu./l, at which time the serum thyroxine concentration (on treatment) was normal.
Discussion
This patient showed unequivocal evidence of hypopituitarism following radiotherapy for nasopharyngeal carcinoma. The delayed pituitary response to stimulation by TRH (Hall et al., 1972) and LH-RH (Vigersky et al., 1977) (Teoh, 1957 radiotherapy to the head, radiation damage to the hypothalamus has been implicated as the mechanism of pituitary dysfunction because the hypothalamus is considered more radiosensitive than the pituitary gland (Larkins and Martin, 1973; Samaan et al., 1975; Rosenthal and Goldfine, 1975) . This radiosensitivity would explain the hypothalamic hypopituitarism in this case despite the inclusion of the pituitary gland in the field of radiation. Although hypothalamic-pituitary abnormalities have been demonstrated after radiation to the head and neck, very few symptomatic cases of hypopituitarism have been described (Larkins and Martin, 1973; Tan and Kunaratnam, 1966) . Previous lack of sensitive hormonal tests of hypothalamic-pituitary function may explain why hypopituitarism has seldom been recognised as a complication of radiotherapy, particularly as the non-specific symptoms of hypopituitarism may be ascribed to the primary malignant disease itself.
Pituitary deficiency has usually been reported as developing several years after radiotherapy (Larkins and Martin, 1973; Samaan et al., 1975) . This patient developed hypopituitarism within one year of direct radiation to the nasopharynx, although the hypothalatnic-pituitary area was probably irradiated 6 months earlier during treatment of presumed brain stem metastases. The time interval between the radiation and clinical hypopituitarism may therefore be much less than the suggested minimum of 5 years (Samaan et al., 1975) .
It seems likely that endocrine abnormalities are a more common complication of radiotherapy to the head and neck than has previously been appreciated (Samaan et al., 1975; Rosenthal and Goldfine, 1976) .
The single most useful screening investigation is probably a serum prolactin level (Samaan et al., 1975) , elevation of which in this context indicates hypothalamic damage. Measurement of serum prolactin concentrations is therefore advisable before and at regular intervals after radiation of the head, to identify this complication at an early stage. Appropriate replacement therapy, as in this case, may transform the patient's clinical condition. 
